Friday, July 10, 2026
🇺🇸 FDA

pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis

PARItec

Pari Pharma GmbH

PARItec clinical programs — 248 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
Status
Public
HQ
Starnberg, DE
Employees
28
Programs
248
Drugs
362
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

PARItec projects

248 ClinicalTrials.gov programs sponsored by PARItec.

PARItec has 248 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

248 programs

Clinical programs

Page 4 of 6

  1. APHP180572

    Pari Pharma GmbH

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  2. APHP190131

    Pari Pharma GmbH

    Primary Sjogren's syndrome

    phase 2 small molecule active

    1 trial

  3. APHP190205

    Pari Pharma GmbH

    PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION

    phase 2 small molecule active

    1 trial

  4. APHP190648

    Pari Pharma GmbH

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  5. APHP200007

    Pari Pharma GmbH

    Severe uveitis of Behçet’s disease

    phase 2 small molecule active

    1 trial

  6. APHP200041

    Pari Pharma GmbH

    Newly diagnosed or relapsing Giant-cell arteritis

    phase 2 small molecule active

    1 trial

  7. APHP200042

    Pari Pharma GmbH

    Patients treated with lithium carbonate for a bipolar disorder treated for at least 5 years and with a urine concentration defect.

    phase 2 small molecule active

    1 trial

  8. APHP200080

    Pari Pharma GmbH

    Newly diagnosed Glioblastoma (IDH wild-type) patients at initial radiological diagnosis eligible for tumor resection, and for the standard of care including concurrent temoradiation followed by adjuvant TMZ with or without Tumor Treating Fields*. (*Tumor Treating Fields is applicable only in participating centers in France)

    phase 2 small molecule active

    1 trial

  9. APHP200132

    Pari Pharma GmbH

    children, adolescents and young adults with Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  10. APHP200133

    Pari Pharma GmbH

    Melanoma

    phase 2 small molecule active

    1 trial

  11. APHP200175

    Pari Pharma GmbH

    subarachnoid hemorrhages of aneurysmal origin (HSAa)

    phase 2 small molecule active

    1 trial

  12. APHP210084

    Pari Pharma GmbH

    first suspected infection with Mycobacterium tuberculosis in the lungs

    phase 2 small molecule active

    1 trial

  13. APHP210416

    Pari Pharma GmbH

    Degenerative shoulder rotator cuff tendinopathy

    phase 2 small molecule active

    1 trial

  14. APHP211000

    Pari Pharma GmbH

    PR3-ANCA granulomatosis with polyangiitis (Wegener’s)

    phase 2 small molecule active

    1 trial

  15. APHP211026

    Pari Pharma GmbH

    Systemic sclerosis

    phase 2 small molecule active

    1 trial

  16. APHP211176

    Pari Pharma GmbH

    Recently diagnosed non favorable Acute Myeloid Leukemias

    phase 2 small molecule active

    1 trial

  17. APHP220273

    Pari Pharma GmbH

    Adult patients aged 18 and over with unicentric hyalino-vascular Castleman's disease

    phase 2 small molecule active

    1 trial

  18. APHP220673

    Pari Pharma GmbH

    newly diagnosed or relapsing deep venous thrombosis related to Behçet’s syndrome

    phase 2 small molecule active

    1 trial

  19. APHP220729

    Pari Pharma GmbH

    Hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  20. APHP220808

    Pari Pharma GmbH

    Fulminant myocarditis

    phase 2 small molecule active

    1 trial

  21. APHP220916

    Pari Pharma GmbH

    -women with an inflammatory HCA proven at histology and with at least one inflammatory HCA of more than 5 cm. -male with at least one inflammatory HCA proven at histology whatever the size and considered as non resectable by the multidisciplinary tumor board

    phase 2 small molecule active

    1 trial

  22. APHP220934

    Pari Pharma GmbH

    AXIAL SPONDYLOARTHRITIS

    phase 2 small molecule active

    1 trial

  23. APHP221107

    Pari Pharma GmbH

    Healthy volunteers : Healthy adults with no history of gastrointestinal disease Patients with IBD in remission

    phase 2 small molecule active

    1 trial

  24. APHP221166

    Pari Pharma GmbH

    gram-negative bacillus pneumonia acquired during mechanical ventilation in patients receiving Extracorporeal Membrane veno-arterial oxygenation

    phase 2 small molecule active

    1 trial

  25. APHP230701

    Pari Pharma GmbH

    paraneoplastic sensory neuropathy with anti-Hu antibodies

    phase 2 small molecule active

    1 trial

  26. APHP230821

    Pari Pharma GmbH

    NEUROENDOCRINE CELLS HYPERPLASIA OF INFANCY

    phase 2 small molecule active

    1 trial

  27. APHP230831

    Pari Pharma GmbH

    Folliculitis decalvans

    phase 2 small molecule active

    1 trial

  28. APHP230845

    Pari Pharma GmbH

    Amyotrophic lateral Sclerosis

    phase 2 other active

    1 trial

  29. APHP230848

    Pari Pharma GmbH

    Non-infectious active cryoglobulinemia vasculitis who are either refractory or intolerant to Rituximab

    phase 2 small molecule active

    1 trial

  30. APHP231308

    Pari Pharma GmbH

    Major patients intoxicated by functional toxicant(s), hospitalized in intensive care and intubated.

    phase 2 small molecule active

    1 trial

  31. APHP240512

    Pari Pharma GmbH

    glioblastoma

    phase 2 small molecule active

    1 trial

  32. APHP240923

    Pari Pharma GmbH

    Sepsis

    phase 2 small molecule active

    1 trial

  33. APHP241595

    Pari Pharma GmbH

    The study population includes adult ICU patients with a hospitalization of more than 48 hours. We have chosen to include patients with or without mechanical ventilation, as sleep disorders affect all ICU patients after 48 hours.

    phase 2 small molecule active

    1 trial

  34. ARTEGENE

    Pari Pharma GmbH

    Severe Combined Immuno-Deficiency (SCID) caused by biallelic mutations in the Artemis gene (DCLRE1C)

    phase 2 small molecule active

    1 trial

  35. Air médical en bouteille, OXYGEN

    Pari Pharma GmbH

    Alternating Hemiplegia of Childhood

    phase 2 small molecule active

    1 trial

  36. Arvisol placebo, Arvisol 150mg

    Pari Pharma GmbH

    Patients with severe Alcohol Use Disorder (according to DSM 5) at entry of a scheduled inpatient alcohol cessation attempt

    phase 2 small molecule active

    1 trial

  37. Atomoxetin STADA 40 mg Hartkapseln, GELATIN

    Pari Pharma GmbH

    Healthy subjects with no neurological or psychiatric disorders

    phase 2 small molecule active

    1 trial

  38. BARICITINIB

    Pari Pharma GmbH

    Juvenile Dermatomyositis

    phase 2 small molecule active

    1 trial

  39. BEVACIZUMAB

    Pari Pharma GmbH

    Adult patients with persistent dyspnea more than 3 months after acute COVID-19 infection.

    phase 2 small molecule active

    1 trial

  40. BEVACIZUMAB, ATEZOLIZUMAB

    Pari Pharma GmbH

    liver transplanted patients with advanced hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  41. CARBOCAINE 20 mg/ml, solution injectable

    Pari Pharma GmbH

    Ischemic stroke

    phase 2 small molecule active

    1 trial

  42. Cell therapy for Inclusion Body Myositis (IBM... for Inclusion Body Myositis

    Pari Pharma GmbH

    Inclusion Body Myositis

    phase 2 other active

    1 trial

  43. D20-P012

    Pari Pharma GmbH

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  44. D20181321

    Pari Pharma GmbH

    recurrent primary supratentorial malignant brain tumors in children

    phase 2 small molecule active

    1 trial

  45. D22-P020

    Pari Pharma GmbH

    Anorexia nervosa

    phase 2 small molecule active

    1 trial

  46. D23-P006

    Pari Pharma GmbH

    Alzeihmer disease

    phase 2 small molecule active

    1 trial

  47. D24-P003

    Pari Pharma GmbH

    Treatment-resistant depression

    phase 2 small molecule active

    1 trial

  48. DEXAMETHASONE for Patients with relapsed/refracto…

    Pari Pharma GmbH

    Patients with relapsed/refractory symptomatic multiple myeloma (MM)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does PARItec have?

248 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.